Bolt Biotherapeutics (BOLT)

Currency in USD
4.960
+0.130(+2.69%)
Closed·
4.7700.000(0.00%)
·
Unusual trading volume
BOLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.5005.200
52 wk Range
3.9109.248
Key Statistics
Prev. Close
4.83
Open
4.9
Day's Range
4.5-5.2
52 wk Range
3.91-9.248
Volume
108.61K
Average Volume (3m)
27.73K
1-Year Change
-38.0769%
Book Value / Share
13.81
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BOLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.000
Upside
+484.68%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Bolt Biotherapeutics News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Compare BOLT to Peers and Sector

Metrics to compare
BOLT
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.4x−0.5x
PEG Ratio
−0.01−0.100.00
Price/Book
0.4x2.1x2.6x
Price / LTM Sales
1.2x80.0x3.2x
Upside (Analyst Target)
44.9%140.2%47.4%
Fair Value Upside
Unlock5.2%6.9%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.000
(+484.68% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Hold---New CoverageApr 06, 2026
H.C. Wainwright
Buy7.00+41.13%-New CoverageOct 20, 2025
Leerink Partners
Hold6.00+20.97%20.00MaintainSep 03, 2025
Lake Street Capital Markets
Buy75.00+1,412.10%4.00MaintainAug 15, 2025
Lake Street Capital Markets
Buy4.00-19.35%-New CoverageMay 20, 2025

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-3.84 / -0.30
Revenue / Forecast
2.5M / 1.01M
EPS Revisions
Last 90 days

BOLT Income Statement

People Also Watch

1.560
INAB
+4.00%
8.780
RLYB
+1.74%
6.430
ALGS
+0.47%
12.1000
AKAN
-1.06%
4.44
CAMP
0.00%

FAQ

What Is the Bolt (BOLT) Stock Price Today?

The Bolt stock price today is 4.960 USD.

What Stock Exchange Does Bolt Trade On?

Bolt is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Bolt?

The stock symbol for Bolt is "BOLT."

What Is the Bolt Market Cap?

As of today, Bolt market cap is 9.530M USD.

What Is Bolt's Earnings Per Share (TTM)?

The Bolt EPS (TTM) is -17.849.

From a Technical Analysis Perspective, Is BOLT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Bolt Stock Split?

Bolt has split 1 times.

How Many Employees Does Bolt Have?

Bolt has 23 employees.

What is the current trading status of Bolt (BOLT)?

As of Apr 28, 2026, Bolt (BOLT) is trading at a price of 4.960 USD, with a previous close of 4.830 USD. The stock has fluctuated within a day range of 4.500 USD to 5.200 USD, while its 52-week range spans from 3.910 USD to 9.248 USD.

What Is Bolt (BOLT) Price Target According to Analysts?

The average 12-month price target for Bolt is 29.000 USD, with a high estimate of 75 USD and a low estimate of 5 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +484.68% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.